Alterity Therapeutics LtdNASDAQ:ATHE
- LAST PRICE3.9100
- TODAY'S CHANGE (%)0.1000 (2.6247%)
- Bid / Lots3.7000/ 2
- Ask / Lots4.0500/ 2
- Open / Previous Close3.8800 / 3.8100
- Day Range
- 52 Week Range
- Volume25,947
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATHE |
|---|---|---|
| 09:42 ET | 510 | 3.88 |
| 09:46 ET | 100 | 3.87 |
| 09:53 ET | 200 | 3.85 |
| 10:04 ET | 600 | 3.83 |
| 10:11 ET | 1000 | 3.85 |
| 10:33 ET | 200 | 3.87 |
| 10:38 ET | 578 | 3.88 |
| 10:44 ET | 100 | 3.9132 |
| 10:56 ET | 5401 | 3.88 |
| 11:14 ET | 200 | 3.8801 |
| 11:36 ET | 100 | 3.88 |
| 11:39 ET | 200 | 3.925 |
| 11:45 ET | 100 | 3.905 |
| 12:01 ET | 250 | 3.9 |
| 12:26 ET | 101 | 3.905 |
| 12:44 ET | 100 | 3.88 |
| 01:31 ET | 500 | 3.91 |
| 01:42 ET | 200 | 3.94 |
| 02:45 ET | 100 | 3.94 |
| 02:50 ET | 1100 | 3.91 |
| 02:54 ET | 200 | 3.91 |
| 02:57 ET | 1800 | 3.92 |
| 02:59 ET | 1000 | 3.9 |
| 03:14 ET | 100 | 3.9 |
| 03:15 ET | 100 | 3.9053 |
| 03:17 ET | 600 | 3.93 |
| 03:21 ET | 7038 | 3.9699 |
| 03:24 ET | 450 | 3.91 |
| 03:26 ET | 200 | 3.935 |
| 03:33 ET | 290 | 3.935 |
| 03:53 ET | 100 | 3.97 |
| 03:55 ET | 300 | 3.91 |
| 03:57 ET | 200 | 3.91 |
| 04:00 ET | 300 | 3.91 |
Jan 25, 2023
BRIEF-Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial In Italy, from 8:15AM ET on Wednesday Jan 25, 2023 by Thomson Reuters
8:15AM ET on Wednesday Jan 25, 2023 by Thomson Reuters
Jan 6, 2023
Alterity Therapeutics Launches 1-for-10 Reverse ADS Split, from 10:37AM ET on Friday Jan 06, 2023 by MT Newswires
10:37AM ET on Friday Jan 06, 2023 by MT NewswiresAlterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation), from 7:25AM ET on Friday Jan 06, 2023 by PR Newswire
7:25AM ET on Friday Jan 06, 2023 by PR Newswire
Jan 3, 2023
Alterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum, from 10:25AM ET on Tuesday Jan 03, 2023 by PR Newswire
10:25AM ET on Tuesday Jan 03, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alterity Therapeutics Ltd | 17.2M | -0.2x | --- |
Lixte Biotechnology Holdings Inc | 12.2M | -1.6x | --- |
Weed Inc | 12.3M | -10.5x | --- |
Kazia Therapeutics Ltd | 17.5M | -0.8x | --- |
Burzynski Research Institute Inc | 12.5M | -14.4x | --- |
Diffusion Pharmaceuticals Inc | 12.6M | -0.8x | --- |
Company Information
Alterity Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead product candidate, ATH434, is being used for the treatment of various Parkinson's disease, Dementia with lewy bodies (DLB) as well as various forms of atypical Parkinsonism, such as Multiple System Atrophy (MSA). ATH434, is a set of molecules designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The Company also has a drug discovery platform generating chemical to intercede in disease processes. ATH434 has been granted Orphan Drug designation for the treatment of Multiple System Atrophy.
Contact Information
- Headquarters
- L 3 460 Bourke StMELBOURNE, VIC, Australia 3000
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Geoffrey Kempler
- Chief Executive Officer
- David Stamler
- Chief Financial Officer
- Kathryn Andrews
- Company Secretary
- Phillip Hains
- Non-Executive Director
- Lawrence Gozlan
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.2M |
|---|---|
Revenue (TTM) | $1.8K |
Shares Outstanding | 4.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.21 |
EPS | $-22.75 |
Book Value | $62.80 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 9,680.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -739,582.40% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
